Atara Biotherapeutics (ATRA) Assets Average (2014 - 2026)

Atara Biotherapeutics (ATRA) has reported Assets Average for 13 consecutive years, with $20.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Assets Average fell 58.54% year-over-year to $20.5 million; the trailing twelve-month figure through Jun 2026 stood at $20.5 million (down 58.54% YoY), and the FY2025 full-year result was $64.7 million, down 52.9% from the prior year.
• Assets Average grew to $20.5 million in Q2 2026 per ATRA's latest filing, from $20.1 million in the prior quarter.
• Across five years, Assets Average topped out at $432.7 million in Q1 2022 and bottomed at $20.1 million in Q1 2026.
• Historically, Assets Average has averaged $190.5 million across 5 years, with a median of $153.3 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Assets Average fell 11.28% in 2022, then sank 79.98% in 2025.
• Over 5 years, Assets Average stood at $372.4 million in 2022, then plunged by 52.43% to $177.1 million in 2023, then slipped by 28.93% to $125.9 million in 2024, then tumbled by 79.98% to $25.2 million in 2025, then fell by 18.61% to $20.5 million in 2026.
• According to Business Quant data, Assets Average over the past three periods registered $20.5 million, $20.1 million, and $25.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.